Are AIs for Breast Cancer Linked With Increased Myocardial Infarction Risk?

Video

This video examines a study that looked at whether aromatase inhibitors are associated with higher myocardial infarction risk in breast cancer patients.

In this video, Sailaja Kamaraju, MD, of the Medical College of Wisconsin, discusses a study that looked at whether aromatase inhibitors (AIs) are associated with higher myocardial infarction risk in breast cancer patients.

The study looked at 5,648 women (67 years and older) from the Surveillance, Epidemiology, and End Results–Medicare (SEER) database with stages I–III breast cancer who were treated with either AIs (n = 4,690) or tamoxifen (n = 958). With over 2 years follow-up there were 22 deaths from myocardial infarction (251 total cases), with 476 deaths from other causes.

Recent Videos
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
3 experts in this video
4 experts are featured in this series.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Related Content